Список литературы

Поставить закладку

Raimondi S., Maisonneuve P., Lowenfels A.B. Epidemiology of pancreatic cancer: an overview // Nature Reviews Gastroenterology &Amp; Hepatology. 2009. Vol. 6. P. 699.
Wolpin B.M. et al. Plasma 25-hydroxyvitamin D and risk of pancreatic cancer // Cancer Epidemiol Biomarkers Prev. 2012. Vol. 21, № 1. P. 82–91.
Duell E.J. et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4) // Ann Oncol. 2012. Vol. 23, № 11. P. 2964–2970.
Huang Y. et al. Prediabetes and the risk of cancer: a meta-analysis // Diabetologia. 2014. Vol. 57, № 11. P. 2261–2269.
Makohon-Moore A., Iacobuzio-Donahue C.A. Pancreatic cancer biology and genetics from an evolutionary perspective // Nat Rev Cancer. 2016. Vol. 16, № 9. P. 553–565.
Pandit S. et al. Incidental liver metastasis in pancreatic adenocarcinoma // Journal of Surgical Case Reports. 2019. Vol. 2019, № 3.
Ansari D. et al. Pancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment // Oncotarget. 2018. Vol. 9, № 5. P. 6644–6651.
Khan M.A.A. et al. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward // Int J Mol Sci. 2017. Vol. 18, № 4. P. 779.
Андрей Дмитриевич Каприн. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). МНИОИ им. П.А. Герцена МНИОИ им. П.А. Герцена-филиал ФГБУ «НМИЦ радиологии» Минздрава России. Москва, 2019. 250 p.
Ducreux M. et al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up† // Annals of Oncology. 2015. Vol. 26, № suppl_5. P. v56–v68.
Трякин А., Бесова Н., Волков Н. Практические рекомендации по общим принципам проведения противоопухолевой лекарственной терапии // Злокачественные опухоли. Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Приказ Министерства здравоохранения и социального развития РФ от 20 ноября 2006 г. N 783 “Об утверждении стандарта медицинской помощи больным со злокачественным новообразованием поджелудочной железы (при оказании специализированной помощи).” Министерство здравоохранения и социального развития РФ, 2006.
Modlin I.M. et al. Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease // Annals of Surgical Oncology. 2010. Vol. 17, № 9. P. 2427–2443.
O’Toole D. et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers // Neuroendocrinology. 2009. Vol. 90, № 2. P. 194–202.
DelMaschio A. et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided ﬁne-needle biopsy. // Radiology. 1991. Vol. 178, № 1. P. 95–99.
Tempero M.A. et al. NCCN Guidelines. Pancreatic adenocarcinoma. Version 1.2019. 2018. P. 155.
Tanaka K., Kida M. Role of endoscopy in screening of early pancreatic cancer and bile duct cancer // Digestive Endoscopy. John Wiley & Sons, Ltd, 2009. Vol. 21, № s1. P. S97–S100.
Pancreatic Cancer Guidelines. Updated: Mar 07, 2019 [Electronic resource]. URL: https://emedicine.medscape.com/article/280605-guidelines#g2 (accessed: 16.12.2019).
Кармазановский Г. Дифференциальная диагностика и определение резектабельности рака поджелудочной железы с помощью МСКТ и МРТ // Анналы хирургической гепатологии. 2019. Vol. 24, № 3. P. 22–35.
Li K.C. et al. Simultaneous measurement of ﬂow in the superior mesenteric vein and artery with cine phase-contrast MR imaging: value in diagnosis of chronic mesenteric ischemia. Work in progress. // Radiology. 1995. Vol. 194, № 2. P. 327–330.
Megibow A.J. et al. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability--report of the Radiology Diagnostic Oncology Group. // Radiology. 1995. Vol. 195, № 2. P. 327–332.
Sheridan M.B. et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: a comparative study with receiver operating characteristic analysis. // American Journal of Roentgenology. 1999. Vol. 173, № 3. P. 583–590.
Buchs N.C. et al. Vascular invasion in pancreatic cancer: Imaging modalities, preoperative diagnosis and surgical management // World J Gastroenterol. 2010. Vol. 16, № 7. P. 818–831.
Holzapfel K. et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer // Abdominal Imaging. 2011. Vol. 36, № 2. P. 179–184.
Motosugi U. et al. Detection of Pancreatic Carcinoma and Liver Metastases with Gadoxetic Acid–enhanced MR Imaging: Comparison with Contrast-enhanced Multi–Detector Row CT // Radiology. 2011. Vol. 260, № 2. P. 446–453.
Li J. et al. Endoscopic Ultrasonography for Tumor Node Staging and Vascular Invasion in Pancreatic Cancer: A Meta-Analysis // Digestive Surgery. 2014. Vol. 31, № 4–5. P. 297–305.
Wyse J.M. et al. Randomized, Double-Blind, Controlled Trial of Early Endoscopic Ultrasound–Guided Celiac Plexus Neurolysis to Prevent Pain Progression in Patients With Newly Diagnosed, Painful, Inoperable Pancreatic Cancer // JCO. 2011. Vol. 29, № 26. P. 3541–3546.
Agarwal B. et al. Endoscopic Ultrasound-Guided Fine Needle Aspiration and Multidetector Spiral CT in the Diagnosis of Pancreatic Cancer // Am J Gastroenterology. 2004. Vol. 99, № 5. P. 844–850.
Farma J.M. et al. PET/CT Fusion Scan Enhances CT Staging in Patients with Pancreatic Neoplasms // Annals of Surgical Oncology. 2008. Vol. 15, № 9. P. 2465–2471.
Borad M.J. et al. Skeletal metastases in pancreatic cancer: a retrospective study and review of the literature // Yale J Biol Med. Yale Journal of Biology and Medicine, 2009. Vol. 82, № 1. P. 1–6.
Sasaki T. et al. Brain metastasis in pancreatic cancer: Two case reports // Medicine. 2019. Vol. 98, № 4.
Lemke J. et al. Brain metastasis in pancreatic cancer // Int J Mol Sci. MDPI, 2013. Vol. 14, № 2. P. 4163–4173.
Bertero Edoardo et al. Linking Heart Failure to Cancer // Circulation. American Heart Association, 2018. Vol. 138, № 7. P. 735–742.
Buza Vitaly, Rajagopalan Bharath, Curtis Anne B. Cancer Treatment–Induced Arrhythmias // Circulation: Arrhythmia and Electrophysiology. American Heart Association, 2017. Vol. 10, № 8. P. e005443.
Naing A. et al. Electrocardiograms (ECGs) in phase I anticancer drug development: the MD Anderson Cancer Center experience with 8518 ECGs // Annals of Oncology. Elsevier, 2012. Vol. 23, № 11. P. 2960–2963.
Покатаев И.А. Консервативное лечение пациентов с местнораспространенным и метастатическим раком поджелудочной железы: соискание ученой степени доктора медицинских наук. Москва, 2020. 268 p.
Daly M. et al. Genetic/familial high-risk assessment: Breast and ovarian, version 2.2017: Featured updates to the NCCN guidelines // Journal of the National Comprehensive Cancer Network : JNCCN. 2017. Vol. 15. P. 9–20.
Qiu M. et al. Pathologic Diagnosis of Pancreatic Adenocarcinoma in the United States: Its Status and Prognostic Value // J Cancer. 2016. Vol. 7, № 6. P. 694–701.
Патютко Ю.И. Гепатопанкреатодуоденальная резекция - есть ли перспективы? // Хирургия. Журнал им. Н.И. Пирогова. 2011. № 8. P. 41–46.
Патютко Ю.И. Проксимальная и дистальная резекция поджелудочной железы с сохранением тела // Хирургия. Журнал им. Н.И. Пирогова. 2012. № 2. P. 70–73.
Unno M. et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP-05). // JCO. 2019. Vol. 37, № 4_suppl. P. 189–189.
Van Tienhoven G. et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC-1): A randomized, controlled, multicenter phase III trial. // JCO. 2018. Vol. 36, № 18_suppl. P. LBA4002–LBA4002.
Reni M. et al. Safety and efﬁcacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial // The Lancet Gastroenterology & Hepatology. 2018. Vol. 3, № 6. P. 413–423.
Gudjonsson B. Pancreatic Cancer: 80 Years of Surgery-Percentage and Repetitions // HPB Surg. 2016. Vol. 2016. P. 6839687–6839687.
Патютко Ю.И. Резекция сосудов в хирургии рака поджелудочной железы // Вестник хирургической гастроэнтерологии. 2012. № 3. P. 21–32.
Varadhachary G.R. et al. Borderline Resectable Pancreatic Cancer: Deﬁnitions, Management, and Role of Preoperative Therapy // Annals of Surgical Oncology. 2006. Vol. 13, № 8. P. 1035–1046.
Патютко Ю.И. Тотальная панкреатэктомия при опухолевом поражении поджелудочной железы // Хирургия. Журнал им. Н.И. Пирогова. 2016. № 9. P. 13–20.
Fathi A.H. et al. Extended Perioperative Antibiotic Coverage in Conjunction with Intraoperative Bile Cultures Decreases Infectious Complications after Pancreaticoduodenectomy // HPB Surgery. 2016. Vol. 2016. P. 1–6.
Базин И., Покатаев И. Место химиотерапии в лечении локализованного рака поджелудочной железы. 2016. Vol. 21, № 4(спецвыпуск 1). P. 20–25.
Massucco P. et al. Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival // Annals of Surgical Oncology. 2006. Vol. 13, № 9. P. 1201–1208.
Kunzmann V. et al. 671OConversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial // Annals of Oncology. 2019. Vol. 30, № Supplement_5. P. mdz247.
Rombouts S.J. et al. Systematic Review of Resection Rates and Clinical Outcomes After FOLFIRINOX-Based Treatment in Patients with Locally Advanced Pancreatic Cancer // Ann Surg Oncol. 2016. Vol. 23, № 13. P. 4352–4360.
Hammel P. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial // JAMA. 2016. Vol. 315, № 17. P. 1844– 1853.
Mukherjee S. et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial // The Lancet Oncology. 2013. Vol. 14, № 4. P. 317–326.
Liao W.-C. et al. Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis // The Lancet Oncology. 2013. Vol. 14, № 11. P. 1095–1103.
Ma S.J. et al. Association of Timing of Adjuvant Therapy With Survival in Patients With Resected Stage I to II Pancreatic Cancer // JAMA Netw Open. 2019. Vol. 2, № 8. P. e199126.
Valle J.W. et al. Optimal Duration and Timing of Adjuvant Chemotherapy After Deﬁnitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study // JCO. 2014. Vol. 32, № 6. P. 504–512.
Neoptolemos J.P. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial // The Lancet. 2017. Vol. 389, № 10073. P. 1011–1024.
Neoptolemos J.P. et al. Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma: The ESPAC-3 Periampullary Cancer Randomized TrialAdjuvant Therapy and Periampullary Adenocarcinoma // JAMA. 2012. Vol. 308, № 2. P. 147–156.
Conroy T. et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer // New England Journal of Medicine. 2018. Vol. 379, № 25. P. 2395–2406.
Oettle H. et al. Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic CancerA Randomized Controlled Trial // JAMA. 2007. Vol. 297, № 3. P. 267–277.
Neoptolemos J.P. et al. A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer // N Engl J Med. 2004. Vol. 350, № 12. P. 1200–1210.
Cartwright T.H. et al. Phase II Study of Oral Capecitabine in Patients With Advanced or Metastatic Pancreatic Cancer // JCO. 2002. Vol. 20, № 1. P. 160–164.
Покатаев И., Тюляндин С. Системная лекарственная терапия метастатического рака поджелудочной железы // Современная онкология. 2016. № 1. P. 20–24.
Burris H.A. et al. Improvements in survival and clinical beneﬁt with gemcitabine as ﬁrst-line therapy for patients with advanced pancreas cancer: a randomized trial. // JCO. 1997. Vol. 15, № 6. P. 2403–2413.
Chin V. et al. Chemotherapy and radiotherapy for advanced pancreatic cancer // Cochrane Database of Systematic Reviews / ed. Cochrane Upper GI and Pancreatic Diseases Group. 2018.
Von Hoff D.D. et al. Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine // N Engl J Med. 2013. Vol. 369, № 18. P. 1691–1703.
Conroy T. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer // N Engl J Med. 2011. Vol. 364, № 19. P. 1817–1825.
Inal A. et al. Gemcitabine Alone versus combination of Gemcitabine and Cisplatin for the Treatment of Patients with Locally Advanced and/or Metastatic Pancreatic Carcinoma: A Retrospective Analysis of multicenter study (Anatolian Society of Medical Oncology) // neo. 2012. Vol. 59, № 03. P. 297–301.
Louvet C. et al. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial // JCO. 2005. Vol. 23, № 15. P. 3509–3516.
Fogelman D. et al. Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma // Cancer Chemother Pharmacol. 2015. Vol. 76, № 3. P. 489–498.
Moore M.J. et al. Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group // JCO. 2007. Vol. 25, № 15. P. 1960–1966.
Dahan L. et al. FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for ﬁrst-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). // JCO. 2018. Vol. 36, № 15_suppl. P. 4000–4000.
Golan T. et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer // N Engl J Med. 2019. Vol. 381, № 4. P. 317–327.
Nagrial A.M. et al. Second-line treatment in inoperable pancreatic adenocarcinoma: A systematic review and synthesis of all clinical trials // Critical Reviews in Oncology/Hematology. 2015. Vol. 96, № 3. P. 483–497.
Pokataev I. Clinical Predictors of Second-Line Chemotherapy Beneﬁt in Patients with Pancreatic Cancer. 2017. P. 6.
Boeck S. et al. Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer // Oncology. 2007. Vol. 73, № 3–4. P. 221–227.
Novarino A. et al. Oxaliplatin, 5-Fluorouracil, and Leucovorin as Second-Line Treatment for Advanced Pancreatic Cancer // American Journal of Clinical Oncology. 2009. Vol. 32, № 1.
Xiong H.Q. et al. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer // Cancer. 2008. Vol. 113, № 8. P. 2046–2052.
Neuzillet C. et al. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts // World J Gastroenterol. 2012. Vol. 18, № 33. P. 4533–4541.
van der Gaag N.A. et al. Preoperative Biliary Drainage for Cancer of the Head of the Pancreas // N Engl J Med. 2010. Vol. 362, № 2. P. 129–137.
Mita N. et al. Second-Line Gemcitabine Plus Nab-Paclitaxel for Patients with Unresectable Advanced Pancreatic Cancer after First-Line FOLFIRINOX Failure // JCM. 2019. Vol. 8, № 6. P. 761.
Colucci G. et al. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study // JCO. 2010. Vol. 28, № 10. P. 1645–1651.
Tschoep-Lechner K.E. et al. Gemcitabine and cisplatin combined with regional hyperthermia as second-line treatment in patients with gemcitabine-refractory advanced pancreatic cancer // International Journal of Hyperthermia. 2013. Vol. 29, № 1. P. 8–16.
Demols A. et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study // Br J Cancer. 2006. Vol. 94, № 4. P. 481–485.
Isayama H. et al. Gemcitabine and Oxaliplatin Combination Chemotherapy for Patients with Refractory Pancreatic Cancer // Oncology. 2011. Vol. 80, № 1–2. P. 97–101.
Viaud J. et al. Gemcitabine as second-line chemotherapy after Folﬁrinox failure in advanced pancreatic adenocarcinoma: A retrospective study // Digestive and Liver Disease. 2017. Vol. 49, № 6. P. 692–696.
da Rocha Lino A. et al. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: a retrospective analysis // J Gastrointest Oncol. 2015. Vol. 6, № 5. P. 511–515.
Chung M.J. et al. Multicenter phase II trial of modiﬁed FOLFIRINOX in gemcitabine- refractory pancreatic cancer // WJGO. 2018. Vol. 10, № 12. P. 505–515.
Taher K. Treatment of Pancreatic Adenocarcinoma with FOLFIRINOX-A Study of Efﬁcacy and Safety in a Saudi Population. 2019. P. 5.
Zaanan A. et al. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study // BMC cancer. 2014. Vol. 14. P. 441.
Berk V. et al. XELOX versus FOLFOX4 as Second Line Chemotherapy in Advanced Pancreatic Cancer // HGE. 2012.
Kang S.P., Saif M.W. Optimal Second Line Treatment Options for Gemcitabine Refractory Advanced Pancreatic Cancer Patients. Can We Establish Standard of Care with Available Data? P. 8.
Yoo C. et al. A randomised phase II study of modiﬁed FOLFIRI.3 vs modiﬁed FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer // Br J Cancer. 2009. Vol. 101, № 10. P. 1658–1663.
CEREDA S. et al. XELIRI or FOLFIRI as Salvage Therapy in Advanced Pancreatic Cancer // Anticancer Research. 2010. Vol. 30, № 11. P. 4785–4790.
Pelzer U. et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-ﬂuorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: A phase III-study from the German CONKO-study group // European Journal of Cancer. 2011. Vol. 47, № 11. P. 1676–1681.
Hu Z.I. et al. Evaluating Mismatch Repair Deﬁciency in Pancreatic Adenocarcinoma: Challenges and Recommendations // Clin Cancer Res. 2018. Vol. 24, № 6. P. 1326–1336.
Le D.T. et al. Mismatch repair deﬁciency predicts response of solid tumors to PD-1 blockade // Science. 2017. Vol. 357, № 6349. P. 409–413.
Hennessy B.T. et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature // Annals of Oncology. Elsevier, 2005. Vol. 16, № 8. P. 1289–1296.
Park S.J., Lee M.A. Oral chemotherapy as second-line treatment option for gemcitabine- refractory advanced pancreatic cancer with poor performance status. // JCO. 2019. Vol. 37, № 4_suppl. P. 405–405.
Burch P.A. et al. Phase III Evaluation of Octreotide <em>versus</em> Chemotherapy with 5- Fluorouracil or 5-Fluorouracil Plus Leucovorin in Advanced Exocrine Pancreatic Cancer: A North Central Cancer Treatment Group Study // Clin Cancer Res. 2000. Vol. 6, № 9. P. 3486.
Neoptolemos J.P. et al. Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial // JAMA. 2010. Vol. 304, № 10. P. 1073.
Bruera E. et al. A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer // Cancer. 1990. Vol. 66, № 6. P. 1279–1282.
Tan C.R. et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics // Front. Physiol. 2014. Vol. 5.
Balaban E.P. et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline // JCO. 2016. Vol. 34, № 22. P. 2654–2668.
Palta M. et al. Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline // Practical Radiation Oncology. 2019. Vol. 9, № 5. P. 322–332.
Кудашкин Н.Е. Стратегия радикального лечения опухолей периампулярной локализации, осложненных механической желтухой // Фарматека. 2012. Vol. 241, № 8. P. 77– 81.
Maire F. et al. Long-term Outcome of Biliary and Duodenal Stents in Palliative Treatment of Patients with Unresectable Adenocarcinoma of the Head of Pancreas // Am J Gastroenterol. 2006. Vol. 101, № 4. P. 735–742.
Jeurnink S.M. et al. Gastrojejunostomy versus stent placement in patients with malignant gastric outlet obstruction: a comparison in 95 patients // Journal of Surgical Oncology. 2007. Vol. 96, № 5. P. 389–396.
Wong G.Y. et al. Effect of Neurolytic Celiac Plexus Block on Pain Relief, Quality of Life, and Survival in Patients With Unresectable Pancreatic CancerA Randomized Controlled Trial // JAMA. 2004. Vol. 291, № 9. P. 1092–1099.
Hameed M., Hameed H., Erdek M. Pain Management in Pancreatic Cancer // Cancers. 2010. Vol. 3, № 1. P. 43–60.
Wolny-Rokicka E. et al. Tolerance and efﬁcacy of palliative radiotherapy for advanced pancreatic cancer: A retrospective analysis of single-institutional experiences // Molecular and Clinical Oncology. 2016. Vol. 4, № 6. P. 1088–1092.
Sangisetty S.L. Malignant ascites: A review of prognostic factors, pathophysiology and therapeutic measures // WJGS. 2012. Vol. 4, № 4. P. 87.
Takahara N. et al. Pancreatic Cancer With Malignant Ascites: Clinical Features and Outcomes // Pancreas. 2015. P. 1.
Scotté F. The importance of supportive care in optimizing treatment outcomes of patients with advanced prostate cancer // Oncologist. AlphaMed Press, 2012. Vol. 17 Suppl 1, № Suppl 1. P. 23–30.
Владимирова Л.Ю., Гладков О.А., Королева И.А. Практические рекомендации по профилактике и лечению тошноты и рвоты у онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Багрова С.Г., Копп М.В., Кутукова С.И. Использование остеомодифицирующих агентов для профилактики и лечения патологии костной ткани при злокачественных новообразованиях // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Сакаева Д.Д., Курмуков И.А., Орлова Р.В. Практические рекомендации по диагностике и лечению фебрильной нейтропении // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Ткаченко П.Е., Ивашкин В.Т., Маевская М.В. Клинические рекомендации по коррекции гепа-тотоксичности, индуцированной противоопухолевой терапией. // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Виценя М.В., Агеев Ф.Т., Гиляров М.Ю. Практические рекомендации по коррекции кардиоваскулярной токсичности противоопухолевой лекарственной терапии // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Королева И.А., Болотина Л.В., Гладков О.А. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию // Злокачественные опухоли : Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Сытов А.В., Зузов С.А., Лейдерман Н.Н. Практические рекомендации по нутритивной поддержке онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Громова Е.Г., Бирюкова Л.С., Джумабаева Б.Т. Практические рекомендации по коррекции нефротоксичности противоопухолевых препаратов // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Сомонова О.В., Антух Э.А., Долгушин Б.И. Практические рекомендации по профилактике и лечению тромбоэмболических осложнений у онкологических больных // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Буйденок Ю.В. Рекомендации по лечению последствий экстравазации противоопухолевых препаратов // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Проценко С.А., Антимоник Н.Ю., Берштейн Л.М. Практические рекомендации по управлению иммуноопосредованными нежелательными явлениями // Злокачественные опухоли: Практические рекомендации RUSSCO. 2020. Vol. 10, № 3s2.
Hulzebos E.H.J. et al. Preoperative Intensive Inspiratory Muscle Training to Prevent Postoperative Pulmonary Complications in High-Risk Patients Undergoing CABG SurgeryA Randomized Clinical Trial // JAMA. 2006. Vol. 296, № 15. P. 1851–1857.
Silver J.K., Baima J. Cancer Prehabilitation: An Opportunity to Decrease Treatment-Related Morbidity, Increase Cancer Treatment Options, and Improve Physical and Psychological Health Outcomes // American Journal of Physical Medicine & Rehabilitation. 2013. Vol. 92, № 8.
Tsimopoulou I. et al. Psychological Prehabilitation Before Cancer Surgery: A Systematic Review // Annals of Surgical Oncology. 2015. Vol. 22, № 13. P. 4117–4123.
Wichmann M. A prospective clinical feasibility study for multimodal “fast track” rehabilitation in elective pancreatic cancer surgery. // Rozhl Chir. 2006. Vol. 85, № 4. P. 169–175.
Gilliland T. et al. Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection // Nutrients. 2017. Vol. 9, № 3. P. 243.
Hijazi Y., Gondal U., Aziz O. A systematic review of prehabilitation programs in abdominal cancer surgery // International Journal of Surgery. 2017. Vol. 39. P. 156–162.
Wren S.M. et al. Postoperative Pneumonia-Prevention Program for the Inpatient Surgical Ward // Journal of the American College of Surgeons. 2010. Vol. 210, № 4. P. 491–495.
Mustian K.M. et al. Comparison of Pharmaceutical, Psychological, and Exercise Treatments for Cancer-Related Fatigue: A Meta-analysis // JAMA Oncol. 2017. Vol. 3, № 7. P. 961–968.
Kinkead B. et al. Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial // Cancer. 2018. Vol. 124, № 3. P. 546–554.
Khorana A.A. et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update // JCO. 2017. Vol. 35, № 20. P. 2324–2328.
Покатаев И., Трякин А. Практические рекомендации по лекарственному лечению рака под- желудочной железы // Злокачественные опухоли. 2018. Vol. 8, № 3s2. P. 401–413.
Azar I. et al. Treatment and survival rates of stage IV pancreatic cancer at VA hospitals: a nation-wide study // J. Gastrointest. Oncol. 2019. Vol. 10, № 4. P. 703–711.
Pokataev I. et al. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer // Journal of Gastrointestinal Cancer. 2019. Vol. 50, № 3. P. 478–484.
Pishvaian M.J. et al. Molecular Proﬁling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative // Clin Cancer Res. 2018. P. 1078-0432.CCR-18–0531.
Aung K.L. et al. Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial // Clin Cancer Res. 2018. Vol. 24, № 6. P. 1344–1354.
Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // American Journal of Clinical Oncology. 1982. Vol. 5, № 6.
Гомболевский В., Лайпан А., Шапиев А. Методические рекомендации по применению критериев ответа солидных опухолей на химиотерапевтическое лечение (RECIST 1.1) // Методические рекомендации №46. № 2018.